Expert Interviews

Daratumumab effectiveness is evaluated as a frontline treatment approach versus in later lines of therapy in patients with multiple myeloma.

Insight on EGFR-mutated non–small cell lung cancer’s impact on treatment options and overall patient prognoses.

Expert panelists consider which regimen they would use, and for what duration, in the setting of transplant-ineligible, newly diagnosed multiple myeloma.

Rita Nanda, MD, leads a discussion of the first clinical scenario, a 41-year-old woman with HER2+ metastatic breast cancer who progressed on docetaxel/trastuzumab/pertuzumab.

To begin the program, an expert panel of leaders in the management of HER2+ metastatic breast cancer provides an overview of the disease landscape.

The panel moves on to review the profile of a patient with transplant-ineligible, newly diagnosed multiple myeloma managed with dara-Rd on the MAIA trial.

Expert perspectives on the current landscape of molecular profiling in patients with non–small cell lung cancer.

Mark Pegram, MD, spoke about using the Breast Cancer Index and Clinical Treatment Score post-5 years to determine outcomes for patients with early-stage hormone receptor–positive breast cancer treated with adjuvant endocrine therapy.

Amrita Y. Krishnan, MD, spoke about where future research in multiple myeloma is headed and a take-home message for her colleagues about teclistamab in heavily pretreated patients.

Aaron Gerds, MD, explains the various types of myelofibrosis and the underlying pathophysiologies.

Srdan Verstovsek, MD, PhD, provides an overview of how myelofibrosis is diagnosed and what criteria are used for risk stratification.

Benjamin Cooper, MD, discussed an ongoing trial examining TAK-676 in combination with pembrolizumab after radiation therapy for patients with non–small cell lung cancer, head and neck cancer, and triple-negative breast cancer.

Roger Li, MD, spoke about responses from the CORE1 trial that examined patients with non–muscle invasive bladder cancer treated with CG0070 plus pembrolizumab.

C. Ola Landgren, MD, PhD, highlights the rationale for the phase 3 DETERMINATION trial, assessing the use of lenalidomide, bortezomib, and dexamethasone plus autologous stem cell transplant and lenalidomide maintenance in patients with newly diagnosed multiple myeloma.

Steven J. Chmura, MD, PhD, spoke about interesting findings from a phase 2R/3 trial of patients with newly oligometastatic breast cancer who were given standard of care systemic treatment with or without stereotactic body radiotherapy and/or surgical resection.

Roger Li, MD, spoke about the mechanism of action of CG0070 used in combination with pembrolizumab to treat patients with non–muscle invasive bladder cancer who were unresponsive to bacillus Calmette-Guerin.

Dr Fonseca discusses approaches for treating frail patients with multiple myeloma and those with high-risk disease.

Before closing their discussion on transplant-eligible, newly diagnosed multiple myeloma, experts consider duration of therapy in this setting.

Panelists briefly review factors they use to select induction therapy for patients with transplant-eligible, newly diagnosed multiple myeloma.

Xiuning Le, MD, PhD, spoke about the use of ctDNA biomarkers and why research should continue for those with advanced non–small cell lung cancer with high MET-amplification being treated with tepotinib.